Literature DB >> 9866420

[Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].

M Tsurusawa, N Katano, T Hirota, M Ito, T Yanase, K Asami, S Koizumi, M Nakayama, T Miyawaki, J Suzumiya, K Nishikawa, H Mugisima, Y Horikoshi, Y Hatae, A Iwai, K Anami, M Kikuchi, K Osima, Y Kaneko, S Kataoka, A Tanaka, M Chin, T Taga, A Watanabe, T Fujimoto.   

Abstract

We report here on the preliminary treatment findings of a CCLSG NHL 960 study that was initiated in March 1996. In this study, 37 patients with non-Hodgkin's lymphoma were assigned to 4 different treatment groups according to disease stage and histology: (1) localized disease; (2) advanced disease, lymphoblastic type; (3) advanced disease, large cell type; and (4) advanced disease, Burkitt type. The first three groups received the modified protocols of the NHL 890 study. Groups 1 and 3 received COPADM induction therapy (CPM, VCR, PRD, ADR, and MTX). After achieving remission, Group 1 received only maintenance therapy consisting of alternate administration of 7 drugs, while Group 3 received additional intensification therapy with combination chemotherapy consisting of MTX and Ara-C, followed by a maintenance phase involving the administration of 9 drugs. Group 2 received COPADL induction therapy (CPM, VCR, PRD, ADR, and LASP) and consolidation/intensification therapies followed by a maintenance phase. Group 4 received short-term intensive COPADM polychemotherapy. Twelve patients with localized with localized disease (stage I-II) and 25 patients with advanced disease (stage III-IV) were enrolled in this study. Except for 2 patients in the advanced disease stages who died earlier in the course of the study, all patients remained in remission.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9866420

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

1.  Primary mediastinal large B-cell lymphoma in Japanese children and adolescents.

Authors:  Tomoo Osumi; Fumiko Tanaka; Tetsuya Mori; Reiji Fukano; Masahito Tsurusawa; Koichi Oshima; Atsuko Nakazawa; Ryoji Kobayashi
Journal:  Int J Hematol       Date:  2016-11-17       Impact factor: 2.490

2.  Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology.

Authors:  Keizo Horibe; Akiko M Saito; Tetsuya Takimoto; Masahiro Tsuchida; Atsushi Manabe; Midori Shima; Akira Ohara; Shuki Mizutani
Journal:  Int J Hematol       Date:  2013-05-24       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.